Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of cyclophosphamide and pemetrexed. Cyclophosphamide is an alkylating agent with immunosuppressive properties that functions as a regulatory T cell inhibitor. Pemetrexed is a multitargeted antifolate drug that inhibits multiple enzymes in the folate pathway. This combination has been studied for the second-line treatment of non-small cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR).
- Other names
- pemetrexed and cyclophosphamide combination
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on cyclophosphamide + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + pemetrexed.